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Cell lines obtained by in vitro transformation of bone marrow with Abelson
murine leukemia virus (A-MuLV) can be divided into three classes: producers,
releasing reverse transcriptase-containing particles and infectious virus; nonpro-
ducers, releasing no viral particles; and defective producers, the most common
phenotype, releasing particulate reverse transcriptase in the absence of infectious
virus. When such cell lines were analyzed 1 to 2 weeks after their isolation,
however, all produced infectious virus. Because these cell lines were carried in
culture, many ceased to release infectious virus but produced defective virions.
One defective producer, SWR4, has been extensively studied. The particles it
produces have the same density as that of virions of Moloney murine leukemia
virus (M-MuLV). The particles contain no 35 to 70S RNA, as determined by
analysis of [3H]uridine-labeled particles, and exhibit no endogenous reverse
transcriptase activity. Although the reverse transcriptase enzyme is of normal
size, the major structural protein of the defective virions has a molecular weight
of 28,000 (p28), in contrast to the p30 of M-MuLV, and no viral glycoprotein was
evident. The defective particles do not appear to arise either from the helper virus
or from Abelson virus. An alteration of the protein of the helper virus is an
unlikely source of p28 because particles produced by lymphoid cells transformed
with another strain of M-MuLV as helper (M-MuLV-TB) contained p28 with an
unaltered cleavage pattern, although M-MuLV-TB p30 differs from M-MuLV
p30. The A-MuLV genome lacks tha capacity to code for the reverse transcriptase
and p28 of the defective virions and therefore cannot be the source of the defective
virions. Clones of fibroblasts infected with A-MuLV only occasionally produce
defective particles. The defective particles therefore probably arose from an
endogenous virus that is preferentially expressed in the class of lymphoid cells
transformed by A-MuLV. This interpretation implies that the majority of A-
MuLV-transformed lymphoid cells completely lose expression of the helper virus
genome.
Abelson murine leukemia virus (A-MuLV) is
a defective retrovirus that causes a rapidly pro-
gressive lymphosarcoma in mice and will induce
growth of transformed lymphoid cells after in
vitro infection of mouse bone marrow cells (21).
At least some A-MuLV-induced lymphoid cell
lines appear to be related to cells of the B-
lymphocyte lineage because they contain im-
munoglobulin-related polypeptides (18, 19, 27,
28, 29, 33).
All A-MuLV-transformed cell lines, producer
or nonproducer, contain a protein of molecular
weight 120,000 that is made under the direction
of the A-MuLV genome (20, 35). This is the only
A-MuLV-specific protein that has been identi-
fied. Like the murine sarcoma viruses, A-MuLV
needs a helper virus to provide its virion struc-
tural proteins.
A-MuLV is also capable of transforming fibro-
blastic cell lines in vitro (25). Transformed fibro-
blastic and lymphoid cell lines that make no
functional helper virus have been isolated, and
A-MuLV can be rescued from such lines by
superinfection with a competent helper virus.
Stocks of A-MuLV can be made with a variety
of helper viruses by superinfecting nonproducer
transformed cells with different competent mu-
rine retroviruses. Although any helper virus can
provide the functions necessary to allow A-
MuLV to transform fibroblasts, the ability of the
virus to transform lymphoid cells is correlated
with the oncogenicity of the helper virus (22,
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24). A-MuLV stocks made with helper viruses of
low oncogenicity are unable to cause Abelson
disease in mice or to transform lymphoid cells.
Certain helper viruses are also unable to estab-
lish a stable infection when used to superinfect
A-MuLV-transformed lymphoid cell lines (22).
Even lymphoid cells producing highly oncogenic
helper viruses have been found to cease virus
production after being carried in culture for sev-
eral months (35).
Although the question has not been directly
investigated previously, our experience with fi-
broblastic cells that are infected with A-MuLV
has been that stable producers and nonpro-
ducers result. The instability of helper virus
production seen with lymphoid cells has not
been evident. Furthermore, when fibroblastic
cells are infected with Moloney murine leukemia
virus (M-MuLV), a representative effective
helper virus, stable producers, and defective pro-
ducers result (26). The defective producers ap-
pear to arise from infection with a variety of
mutant proviruses giving rise to a variety of
stable phenotypes.
The disparity between the apparently stable
fibroblast-M-MuLV relationship and the appar-
ently unstable relationship between A-MuLV-
transformed lymphoid cells and helper viruses
led us to undertake a systematic investigation of
virus production by A-MuLV-transformed cells.
We report here that most A-MuLV-transformed
lymphoid cells evolve to a state where no helper
virus production is evident but where the cells
make a highly defective particle that probably
arises from an endogenous provirus in the orig-
inal target cell.
MATERIALS AND METHODS
Cells. NIH/3T3, BALB/3T3, SC-1, XC, and FG-10
cells were grown in Dulbecco modified Eagle medium
supplemented with 10% calf serum (Microbiological
Associates). Transformed lymphoid cell lines were de-
rived from individual foci of A-MuLV-infected bone
marrow cells and adapted to growth in RPMI-1640
medium supplemented with 10% heat-inactivated fetal
calf serum and 50 uM 2-mercaptoethanol (Kodak
Chemical Co.) (22). SWR4 was derived from an SWR/
J mouse; 242, TB-li, and TB8-5 were derived from
NIH/Swiss mice; 18-4 was from a BALB/cJ mouse;
and BR48 was from a C57BR/cdJ mouse. Superin-
fected cell lines are designated /M-MuLV.
The series of transformed fibroblasts was derived
by infecting NIH/3T3 cells at an approximate multi-
plicity of infection (MOI) of 0.025 focus-forming unit
(FFU) and 0.05 plaque-forming unit (PFU) per cell.
After a 1.5-h adsorption period, the cells were washed
and trypsinized, mixed with agar-containing medium,
and plated in a final concentration of 0.3% agar at 103
to 104 cells per 10-cm plate. After 17 days at 38°C,
transformed colonies were visible by eye and were
picked by using a Pasteur pipette. They were trans-
ferred to 60-mm dishes and grown up and tested for
release of reverse transcriptase activity and virus by
XC and focus assays.
Viruses. A-MuLV stocks were routinely prepared
from an NIH/3T3-derived, A-MuLV-transformed cell
line, ANN-1 (25), rescued with M-MuLV-1 (6). A
second, clonally derived fibroblast nonproducer cell
line, A2, was made by infecting NIH/3T3 cells with A-
MuLV(M-MuLV-1) at an MOI of 0.005 FFU and 0.01
PFU per cell and cloning in agar as described above
for NIH/3T3 cells infected with A-MuLV. Of the 13
clones isolated, A2 is 1 of 3 that did not release
infectious virus. M-MuLV-TB (a gift of P. Wong,
University of Illinois) was used to rescue A-MuLV
from A2 cells by infecting them at an MOI of 0.5. After
adsorption, cells were trypsinized and plated in micro-
titer wells at approximately 0.2 cell per well. After 15
days, clones were transferred to dishes. Of the 11
clones tested, only 1 produced virus.
In all cases, virus stocks were prepared from expo-
nentially growing cells. Culture fluids were centrifuged
at low speed and filtered through 0.45-nm filters (Mil-
lipore Corp.) before use. A-MuLV and M-MuLV were
titrated by the standard fibroblast transformation as-
say for A-MuLV (25) and the XC (23) or the S+L-
plaque assay (2) for M-MuLV. All infectivity assays
were done in the presence of8 jig ofpolybrene (Aldrich
Chemical Co.) per ml.
Reverse transcriptase assay. Exogenous reverse
transcriptase assays were performed as described by
Rosenberg and Baltimore (22) by using polyriboade-
nylate and oligodeoxythymidylate. Virus used to de-
termine the ratio of endogenous to exogenous activity
was collected by centrifugation, purified by banding in
a density sucrose gradient, centrifuged, and suspended
in 0.5 mi of 20 mM Tris (pH 8.3). The endogenous
assay was carried out at 37°C in a 0.1-ml reaction
mixture containing 60mM Tris (pH 8.3), 60 mM NaCl,
6 mM Mg acetate, 20mM dithiothreitol, 1 mM dATP,
1 mM dCTP, 1 mM dGTP, and 100 ,uCi of [3H]dTTP
(40 Ci/mmol). Duplicate test tubes were removed at
1, 2.5, and 5 h and stored on ice before precipitation
with trichloroacetic acid. The reaction rate was deter-
mined by linear regression analysis.
Analysis of virion density and RNA. Approxi-
mately 109 exponentially growing lymphoid cells were
labeled with 10 ,uCi of [3H]uridine per ml for 3 h at 107
cells per ml, followed by the addition of two volumes
of normal medium. After an additional 4 h, superna-
tants were harvested and clarified, and the virus was
collected by centrifugation. The virus was resus-
pended, sonicated, and layered on a 25 to 45% sucrose
gradient in 50mM Tris (pH 7.5)-100 mM NaCl-1 mM
EDTA. The gradient was centrifuged at 35,000 rpm
for 12 to 18 h at 4°C. Fractions of 0.5 ml were collected
and assayed as described above.
The analysis of virion RNA was done on labeled
virions produced and purified as described above. The
virus from the gradient was lysed in 2% sodium dodecyl
sulfate (SDS), and the RNA was purified by phenol-
chloroform extraction and ethanol precipitation. RNA
was analyzed by sucrose gradient centrifugation by the
method of Kerr et al. (10).
Protein analysis. Virions were purified by sucrose
gradient as described above and suspended in 20 mM
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Tris (pH 8.3). They were lysed by the addition of NP-
40 (final concentration, 1%) and heated at 67°C for 5
min. Iodination was performed by using lactoperoxi-
dase (17) or chloramine T (8). Immunoprecipitation
was performed by using sera shown to be specific for
M-MuLV p30 and gp7O (16) by techniques described
in detail elsewhere (34). Briefly, labeled virus was
precleared with normal serum and Staphlycoccus au-
reus Cowan strain 1 (11). Immunoprecipitates were
then made by incubating the supernatants with 5 p1 of
serum and then collecting antigen-antibody complexes
with S. aureus. SDS-polyacrylamide gel electropho-
resis was performed on the discontinuous stacking
system ofLaemmli (12). Gels were stained with 0.025%
Coomassie blue-10% acetic acid (vol/vol)-25% isopro-
panol (vol/vol) and then destained in 10% acetic acid.
After drying, autoradiography was done using Kodak
No-Screen film.
Peptide digest analysis was performed by the
method of Cleveland et al. (4), except that dried gels
were used. After cutting out the band from the dried
gel, the piece was rehydrated in 10 ml of a solution
containing 0.125 M Tris (pH 6.8), 0.1% SDS, and 1
mM EDTA. This solution was changed four times
over 1 h. The gel slice was then placed on a new gel,
and 10 pl containing either 100 jig of S. aureus pro-
tease, 100 ,ug of papain, or 1 ug of pronase per ml was
added to the indicated slots. After electrophoresis, the
gel was stained and dried and autoradiography was
performed.
RESULTS
Virus production by A-MuLV-trans-
formed lymphoid celis. A-MuLV-trans-
formed bone marrow cells arising as single foci
in the agarose transformation assay (21) were
adapted to growth in liquid medium and tested
for virus production using both infectivity and
reverse transcriptase assays (Table 1). Three
classes of cell lines were found: producers (e.g.,
18-4), cell lines producing large amounts of par-
ticulate reverse transcriptase and high titers of
infectious and transforming virus; nonproducers
(e.g., BR48), cell lines releasing no reverse tran-
scriptase or infectious virus; and defective pro-
ducers (e.g., SWR4 and 242), cell lines releasing
particulate reverse transcriptase in the absence
of detectable plaque-forming or focus-forming
virus. The A-MuLV genome was present in non-
producer and defective producer cell lines be-
cause it could be rescued from them by the
addition of a helper virus such as M-MuLV
(Table 1). A-MuLV stocks prepared after rescue
were indistinguishable by in vivo and in vitro
infectivity assays from A-MuLV released by pro-
ducer cell lines such as 18-4.
Cocultivation studies with the defective pro-
ducers, 242 and SWR4, were carried out to de-
termine if any infectious virus could be detected
(Table 2). The lymphoid cell lines were treated
with mitomycin C and cultivated with NIH/3T3,
BALB/3T3, and SC-1 cells for the detection of
ecotropic virus and CCL64 (mink lung cells) for
the detection of xenotropic virus. The indicator
cells were then carried as exponentially growing
cultures for 3 to 6 weeks and assayed for reverse
transcriptase production. No infectious eco-
tropic or xenotropic virus was recovered from
SWR4 or 242 in these tests. No infectious virus
TABLE 1. Characteristics ofA-MuLV-transformed lymphoid cell lines
Supernatant Induction of Abelson dis-
reverse tran- PUr- FUe ease'
ascriptase ac- PUr- FUe- Lymphoid Ma aCell line tViy leased' leasedc UCellnI i (Xlo-3) (XlO-3) foci/105 FFUd Mean la-(cpm x i07'/ Incidence tent period
106 cells) (days)
18-4 240 14 7 570 6/6 22
BR48 0.3 0 0 NDf ND
BR48/M-MuLV 55 6 5 60 8/8 24
SWR4 23 0 0 ND 0/9
SWR4/M-MuLV 300 80 20 33 3/3 21
242 2 0 0 ND ND
242/M-MuLV 62 5 2 1,000 5/7 42
a Lymphoid cell lines were derived by the in vitro transformation assay (21) and those designated /M-MuLV
had been superinfected with the indicated virus.
b Reverse transcriptase assays were performed by using an oligo(dT) primer and poly(rA) template as
described in Materials and Methods. Values of less than 500 cpm were considered to be background.
e Plaque-forming units of M-MuLV were determined by the XC plaque assay (23). Focus-forming units of A-
MuLV were determined by the fibroblast transformation assay of Scher and Siegler (25).
d The efficiency of virus stocks to transform bone marrow cells was determined by using NIH/Swiss bone
marrow (21).
'In vivo inoculations were done intraperitoneally in neonatal NIH/Swiss mice using filtered reverse tran-
scriptase-positive supernatants. All mice were observed for 5 to 6 months.
fND, Not determined.
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TABLE 2. Release of infectious virus by defective
producer lymphoid cellsa
Cocultivated with:b
Cell line NIH/ BALB/ SC-i CCL64
3T3 3T3 S- C6
242 0.6 0.4 0.4 0.3
SWR4 0.7 0.4 0.2 0.3
SWR4/M-MuLV 114 28 140 0.4
a 1 X 106 lymphoid cells were treated with 25 jig of
mitomycin C for 30 min and mixed with adherent cells
at a ratio of 3:1. After 48 h, the monolayers were
washed, and adherent cells were maintained as expo-
nentially growing cultures. Reverse transcriptase ac-
tivity in the culture fluids was determined 3 weeks
after cocultivation. Negative cultures were continued
and retested 6 weeks after cocultivation.
b Values were obtained from the reverse transcrip-
tase assay and are expressed as counts per minute x
10-3. Values less than 0.7 were considered negative.
was recovered from SWR4 even after treatment
with iododeoxyuridine (3) and cocultivation with
indicator cells (data not shown), but infectious
ecotropic virus produced by SWR4 superin-
fected with M-MuLV (SWR4/M-MuLV) was
readily detectable (Table 2).
The proportion of cell lines with the defective
producer phenotype was very high when ran-
domly isolated cell lines were obtained from
various mouse strains including NIH/Swiss,
SWR/J, BALB/cAN, C57L/J, and C57BL/6J.
To systematically determine the frequency of
defective producers, several series of lymphoid
clones from individual experiments were isolated
and monitored for reverse transcriptase and in-
fectious virus production after various times
(Table 3). In experiments 1 and 2, clones were
adapted to liquid medium, a procedure that
takes 3 to 6 weeks once the foci are removed
from agarose. Most clones in these experiments
were defective producers. In experiment 3, cell
lines were tested during their adaptation to con-
tinuous culture. One to two weeks after remov-
ing the cells from agarose, 57% of the focal
isolates produced large amounts of virus (>103
PFU per 106 cells). After 1 month in liquid
medium, the majority of cultures still released
virus, but the amount of virus produced by the
cells had decreased and some cell lines now
displayed the defective phenotype. After 2
months in vitro (data not shown), three cultures
classified at 1 month as low producers were
retested and had become defective producers.
One cell line classified at 1 month as a high
producer was retested at 2 months and was
stable, as were two cell lines designated as de-
fective producers.
The interaction of M-MuLV with A-MuLV-
transformed lymphoid cells differs from its in-
teraction with fibroblasts in two ways. First, the
interaction of M-MuLV with fibroblasts is a
stable one. As mentioned previously, subclones
of M-MuLV-infected fibroblasts are all virus
producers (26). In a variety of situations we have
examined previously cloned, infected fibroblasts
for loss of virus production and have not ob-
served such loss. Second, transformation of fi-
broblasts with A-MuLV and M-MuLV helper
generated a different pattern ofphenotypes from
that seen in lymphoid transformants (Table 4).
Mainly producer or nonproducer cells were
formed and the one defective producer in Table
4 may represent a spontaneous mutation be-
cause such mutant M-MuLV is often produced
(26).
Characterization of the defective virions.
One defective producer line was chosen for in-
tensive study because it produced more defec-
tive particles than the others. This line, SWR4,
released sedimentable particles containing re-
verse transcriptase (Table 1). To determine if
the particles were virion-like, SWR4 cells were
labeled with [3H]uridine and the labeled, re-
TABLE 3. Phenotypes of lymphoid cell lines
Expt no.
(time of assay)
Phenotypea 1 2 3
(1-2 (1-2 1-2
mo.) mo.) weeks 1 mo.
High producers 8b 25 57 21.5
Low producers 0 12.5 43 57
Defective 77 62.5 0 21.5
producers
Nonproducers 15 0 0 0
Total number of 13 8 14
clones assayed
a Transformed lymphoid cell lines were derived by
infection of NIH/Swiss bone marrow with A-MuLV.
After a 1.5-h adsorption period, cells were plated in
agarose-containing medium, and after 10 to 11 days,
individual foci were picked and grown in liquid me-
dium for the times indicated above before testing.
High producers were cell lines producing more than
103 PFU/106 cells, as assayed using the FG-10 S+L-
assay, and having reverse transcriptase levels greater
than 10,000 cpm/106 cells. Low producers released less
than 103 PFU/106 cells (with most cell lines in this
category releasing less than 100 PFU/106) and had
more than 500 cpm in the reverse transcriptase assay.
Defective producers released no PFU or FFU and had
greater than 500 cpm in the reverse transcriptase
assay. Nonproducers released no PFU or FFU and
had less than 500 cpm in the reverse transcriptase
assay; less than 500 cpm is background.
b Values represent percentage of clones in that cat-
egory except for the last line of data.
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TABLE 4. Phenotypes offibroblast clones
transforned by A-MuLVa
No. of Reverse transcrip-
Class clones in tase assayb
category (cpm x 10-3)
Normal producers 10 100-400
Nonproducers 6 <0.5
Defective producers 1 1.5
Total number tested 17
a Clones were isolated after infection of NIH/3T3
cells with A-MuLV(M-MuLV) and selection in agar as
described in Materials and Methods. Clones were pas-
saged for 2 weeks before testing. After overnight in-
cubation, supernatants were harvested from subcon-
fluent 10-cm plates and analyzed by XC and focus
assay. Producers are defined as releasing infectious
virus detectable in both assays, whereas nonproducers
and defective producers have no activity in either.
b Before analysis by reverse transcriptase assay (22)
supernatants were concentrated 10-fold by centrifu-
gation. Backgrounds were not subtracted; values of
less than 500 cpm were not significantly above back-
ground.
leased particles were sedirnented to equilibrium
in a 25 to 45% sucrose gradient (Fig. 1). M-MuLV
labeled with 32p was used as an internal stan-
dard, and the particles from the superinfected
producer lymphoid line, SWR4/M-MuLV, were
analyzed in parallel. The defective producer re-
leased 3H-labeled particles containing reverse
transcriptase activity that were of the same den-
sity as M-MuLV and the infectious virions of
SWR4/M-MuLV.
To study their morphology, SWR4 and 18-4
particles were isolated, negatively stained, and
examined by electron microscopy (Fig. 2). Al-
though both preparations contained type C par-
ticles, the 18-4 particles had readily evident
spikes characteristic of glycoprotein, but the
SWR4 particles lacked such spikes.
To examine the RNA content of these parti-
cles, [3H]uridine-labeled RNA was extracted
from the purified particles and displayed on a 15
to 30% sucrose gradient (Fig. 3). The producer,
18-4, released particles having RNA that sedi-
mented at 70S as well as low-molecular-weight
RNA, presumably mainly tRNA, that remained
near the top of the gradient. The particles from
SWR4 cells contained no demonstrable large-
molecular-weight RNA, although it did contain
some low-molecular-weight RNA.
As an alternative method ofstudying the RNA
of the particles, we compared exogenous reverse
transcriptase activity to endogenous activity in
defective and nondefective particles. In the ex-
ogenous assay, oligodeoxythymidylate primer
and polyriboadenylate template were added to
the reaction mix to quantitate enzymatic activ-
ity. The endogenous assay relied on the virions
to supply 70S genomic RNA and tRNA, the
natural template and primer. The ratio of en-
dogenous to exogenous activity should be a
measure of the relative content ofgenomic RNA.
SWR4 particles contained only 4 to 10% of the
endogenous activity in particles from the normal
producer, 18-4 (Table 5). This result confirms
the lack of high-molecular-weight RNA in de-
fective virions.
Proteins of defective virions. To examine
the size of the reverse transcriptase contained in
defective and standard virus, purified virions
were lysed with NP-40 and their proteins were
fractionated by centrifugation through 5 to 20%
glycerol gradients. Assay of the fractions re-
vealed no significant difference in size between
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FIG. 1. Isopycnic sedimentation ofnormal and de-
fective virions on sucrose gradients. [3H/uridine-la-
beled virions were prepared and sedimented on 25 to
45% sucrose gradients as described in Materials and
Methods. Portions of each fraction were assayed for
reverse transcriptase activity or counted directly to
determine [3H]uridine. 32P-labeled M-MuLV was in-
cluded in each gradient as an internal standard. (A)
Virions from SWR4/M-MuLV, a cell line releasing
infectious virus. (B) Defective virions from SWR4.
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FIG. 2. Electron microscopy ofparticles ofstandard and defective virions. Virions were purifiecl by density
gradient centrifugation, placed on carbon-coated copper grids and negatively stained with phosphotungstan-
ate (9). (A) Standard virions from SWR4/M-MuLV. (B) Defective virions from SWR4. Bar = 100 nm.
B. SWR4
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FIG. 3. Sucrose gradient centrifugation analysis
of RNA from SWR4 and 18-4. [3Hluridine-labeled
virions were prepared, and RNA was extracted, pu-
rified, and analyzed as described in Materials and
Methods.
the enzyme of the defective virions and that of
infectious virions (Fig. 4).
The major structural protein of standard and
defective virions was analyzed by labeling deter-
TABLE 5. Exogenous and endogenous reverse
transcriptase assays of standard and defective
particlesa
Exogenous Endogenous Ratio of
Partcle de reverse tran- reverse tran- endoge-Particles de- scriptase scriptase nous to
rived from: (cpm x (cpm x exogenous
10-5) 10-3) relative to
NIH/3T3b 5.0 ± 0.8 9.5 ± 0.6 1.0
SWR4/M- 6.0 ± 2.8 14.7 ± 1.9 1.29
MuLV
SWR4 2.1 ± 0.4 0.2 ± 0.02 0.04
aExogenous and endogenous reverse transcriptase
assays were performed as described in Materials and
Methods. In a separate experiment, the ratio of en-
dogenous to exogenous reverse transcriptase assay for
SWR4 particles relative to M-MuLV was 0.1.
b A cell line releasing standard M-MuLV.
gent-disrupted virions with 125I. These prepara-
tions were then immunoprecipitated with sera
specific for M-MuLV p30 protein and glycopro-
tein (16) and analyzed by polyacrylamide gel
electrophoresis (Fig. 5). The normal producer
contained the expected p30 (lane Al) and gp7O
(lane B1). The defective producer contained a
major structural protein that migrated with an
apparent molecular weight of 28,000 (lane A3).
A p28 has also been detected in particles from
two other A-MuLV-transformed NIH/Swiss de-
fective producer cell lines (242; TB8-5, see be-
low). Although we could detect no glycoprotein
on the defective virions, the detection level for
this protein is so poor that it may not be truly
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absent. Furthermore, there could be a glycopro-
tein present that was not precipitated by the
antiserum used here. The superinfectability of
SWR4, BR48, and 242 (Table 1), however, ar-
gues that there is little ecotropic glycoprotein
present on the surface of the defective producer
cells. The lack of glycoprotein in the defective
virus is consistent with the absence of spikes
when particles were examined by electron mi-
croscopy.
One possible origin of p28 could be processing
of the M-MuLV gag polyprotein to generate p28
rather than p30. To determine if the defective
producers were intrinsically able to synthesize
p30 from the M-MuLV gag polyprotein, the
virion proteins from SWR4/M-MuLV were an-
alyzed. A mixture ofp28 and p30 was discernable
(Fig. 5, lane A2), implying that the defective
producers can process the M-MuLV polyprotein
normally.
Origin of defective particles. The genetic
information coding for the defective virions
might originate in the Abelson genome, in an
altered helper virus, or in an endogenous virus.
The Abelson virus genome is an unlikely source
of the information for the defective virions be-
cause it codes for a protein, P120, that lacks
most of the antigenicity of p30, does not give rise
to detectable p30-like cleavage products, and
lacks determinants of reverse transcriptase (35,
20). Furthernore, heteroduplex analysis has
demonstrated that the regions of A-MuLV ho-
mologous to M-MuLV are of insufficient size to
code for all of p30 and reverse transcriptase
(Shields et al., unpublished data).
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FIG. 4. Glycerol gradient centrifugation ofreverse
transcriptase from a defective producer, TB8-5, and
a normal producer, TB11. Disrupted virions were
sedimented on a 5 to 20% glycerol gradient, and the
presence of the enzyme was quantitated by using the
exogenous reverse transcriptase assay as described
in Materials and Methods (34). 125I-labeled bovine
serum albumin and fluoresceinated goat immuno-
globulin G were centrifuged in a parallel gradient as
markers. Symbols: (0) TB11; (0) TB8-5.
1 2 3
iwt.-
A,>:
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gp 69/70-
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FIG. 5. Analysis ofproteins contained in virions.
Immunoprecipitates of "251-labeled virions were ana-
lyzed by polyacrylamide gels as described in Mate-
rials and Methods. (A) Antiserum against p30; (B)
antiserum against glycoprotein. Virion samples were
derivedfrom cell lines: (1) 18-4; (2) SWR-4/M-MuLV;
(3) SWR4.
Possible sources for the p28 were M-MuLV
and the only known SWR/J endogenous virus
(32). To compare the defective virion p28 with
the major structural proteins of these viruses,
virions were purified from SWR4 cells, 18-4 cells,
and from SC-1 cells infected with the SWR/J
virus. After disruption of the virions, the pro-
teins were iodinated, immunoprecipitated with
a serum specific for p30, and displayed by elec-
trophoresis through an SDS-polyacrylamide gel.
The bands containing the major structural pro-
tein were identified by autoradiography and ex-
cised from the dried gel. After rehydration, the
gels slices were placed on a new gel and mixed
with unlabeled M-MuLV p30, and the proteins
were compared by partial proteolytic cleavage
by the method of Cleveland et al. (4). Coomassie
blue staining of the gel provided an internal
standard with which to compare the autoradi-
ogram and demonstrated that equal digestion
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occurred in all samples (Fig. 6). The major struc-
tural protein of the endogenous SWR/J virus
migrated with an apparent molecular weight of
27,000 (this difference in migration is evident in
Fig. 6 when the autoradiogram is compared with
p30--- _
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0
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(1)n-
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the Coomassie blue stain). Analysis of digests by
papain, pronase, and S. aureus protease dem-
onstrated the marked similarity of p28 to the
p30 of M-MuLV and the p27 of the SWR/J
endogenous virus. There are, however, minor
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FIG. 6. Comparison of virion proteins by partial proteolytic cleavage. Purified virus was iodinated, and
the major structural protein was purified and analyzed by partial digestion with the indicated protease
during electrophoresis through a polyacrylamide gel (see Materials and Methods). Before digestion, each
preparation of iodinated protein was mixed with unlabeled M-MuLV p3O. The autoradiogram displays the
digests of the major structural proteins from: (1) 18-4, a normal lymphoid producer; (2) SWR4, a lymphoid
defective producer; (3) an SC-1 cell line releasing the SWR/J endogenous virus. The arrow indicates the
difference in peptide patterns between the SWR/J endogenous virus and the other viruses. The Coomassie
blue stain demonstrates the cleavage pattern of unlabeled M-MuLVp3O.
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Undigested S
2 3
i. Aureus Proteose the major structural protein. Although thisstrain of virus contains a major structural pro-I X lOX tein of molecular weight 30,000, the cleavage
2 3 2 3 pattern of its p30 is different from that of our
standard M-MuLV. Therefore, a stock of Abel-
son virus was produced with M-MuLV-TB
helper, and this was used to derive a series of
W ^ > * lymphoid clones from an NIH/Swiss mouse.
Again a number of nornal and defective pro-
ducers was isolated and the defective virions of
* * the tested cell line were shown to contain p28.
W When the proteins were compared by digestion
with S. aureus protease (Fig. 7), a characteristic
peptide difference was visible between the p30
of the lymphoid producer releasing standard M-
MuLV (lanes 1) and M-MuLV-TB (lanes 2). The
p28 of the defective producer derived from the
stock containing M-MuLV-TB appeared un-
FIG. 7. Analysis of defective virions using M-
MuLV-TB. Analysis was done as described in the
legend to Fig. 6 and Materials and Methods, except
that the samples indicated by IX were digested with
a solution containing 100 ,g ofS. aureusprotease per
ml and those indicated by lOX employed 1 mg of S.
aureus protease per ml. The autoradiogram displays
the digests of: (1) p30 from SWR4/M-MuL V, a clone
which releases standard M-MuLV; (2) p30 from
TBll, a lymphoid producer releasing M-MuL V-TB;
(3) p28 from TB8-5, a defective lymphoid producer.
differences between them, especially one band
present in the SWR/J virus cleaved with S.
aureus protease that was absent in the digests
of the other two (arrow, Fig. 6; the lack of this
peptide in the SWR4 p28 is more evident in the
data presented in Fig. 7). Furthermore, many of
the cleavage products ofp28 migrated somewhat
faster than those of M-MuLV p30, presumably
reflecting the smaller size of the original protein.
The similarity of the digestion products from
M-MuLV p30 and the defective particle p28 and
the similar sedimentation of reverse transcrip-
tase from the two virion preparations suggested
that a possible origin of the defective virions
could be through an alteration of the helper
virus. When M-MuLV virus infects fibroblasts it
mutates at a rapid rate but produces a variety of
defects, none ofwhich include a smaller p30 (26).
By contrast, the particles produced by the de-
fective lymphoid producers are homogeneous in
phenotype to the extent that all contain reverse
transcriptase and lack infectivity in the XC and
focus assays, and three have p28. The lymphoid
cells could, however, either cause or select for a
particular defect within the helper virus. This
was tested by using as a helper another strain of
M-MuLV (M-MuLV-TB) that can be distin-
guished from our standard M-MuLV and study-
ing the resulting defective virions for changes in
changed and similar to that of M-MuLV (lanes
3), however, suggesting that p28 is not derived
from the helper virus. It is also evident from the
lOx digests (Fig. 7) that M-MuLV and M-
MuLV-TB contain an extra band not present in
p28.
DISCUSSION
Lymphoid cells transformed byA-MuLV have
very different properties from A-MuLV-trans-
forned fibroblasts. Lymphoid lines can be di-
vided into three classes: producers, releasing in-
fectious virus; nonproducers; and defective pro-
ducers, releasing particulate reverse transcrip-
tase but no infectious virus. The defective pro-
ducers are the predominant phenotype isolated
in each of the mouse strains tested. Clones of
fibroblasts transformed with A-MuLV(M-
MuLV) were predominantly producers or non-
producers. In the series of transformed fibro-
blasts described here, only one clone released
reverse transcriptase-containing particles that
were not infectious in the XC and focus assays.
It is probable that this clone is the result of a
spontaneous mutation of M-MuLV, an event
that occurs frequently in the helper virus (26).
Because the level of reverse transcriptase is
quite low in the lymphoid defective producers,
it is possible that nonproducer fibroblasts may
also release these particles but at a level not
detectable in our assay.
The lymphoid defective producers may all
have initially contained a competent helper virus
genome because analysis of lymphoid clones be-
fore they were fully adapted to liquid medium
showed that many produce infectious virus, al-
though often at low titers. Furthermore, the
inability of some helper viruses to make A-
MuLV competent to transform lymphoid cells-
a behavior that does not correlate with helper
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virus tropism-suggests that the helper may
play an active role in the early intracellular
stages ofA-MuLV lymphoid cell transformation
(22, 24). Which helper virus function is needed
and why oncogenicity of the helper correlates
with lymphoid cell transformation but not fibro-
blast transformation are unanswered questions.
As lymphoid transformants grow, many cease
to release infectious virus but continue to release
defective virions. We have previously shown that
A-MuLV-transformed lymphoid cells infected
with helper virus may cease virus production as
they are passaged (22, 35). This does not appear
to be solely due to selection, because repeatedly
cloned cell lines have been found to cease virus
production. Lymphoid cells appear able to reg-
ulate helper virus gene expression because when
A-MuLV nonproducer lymphoid cells are super-
infected with a helper of low oncogenicity, they
cease releasing virus after a few days. Even some
A-MuLV-transformed lymphoid cells producing
a helper virus of high oncogenicity have been
found to cease virus production when carried in
culture for several months. Cell lines derived
from tumors induced by the in vivo inoculation
of Friend MuLV complex into certain mouse
strains also ceased to release infectious virus as
the cells were passaged in vitro (7). By contrast,
fibroblasts seem to stably release virus once a
productive infection is established even with a
helper of low oncogenicity.
The defective particles released by the lymph-
oid cells were found to have the density of nor-
mal virions and to contain reverse transcriptase
of normal size. However, no 70S RNA was found
as determined by analysis of [3H]uridine-labeled
virions and by the endogenous reverse transcrip-
tase assay. The low level of activity noted in the
endogenous assays probably reflects transcrip-
tion of small RNA packaged in the virions. It
has been previously shown that virions lacking
70S RNA are produced after treatment of cells
with actinomycin D, and they also contain low-
molecular-weight RNA (13, 15). It is possible,
though, that these analyses could be misleading
if there were a relative overabundance of reverse
transcriptase activity in the virions.
The defective virion's major structural protein
migrates with an apparent molecular weight of
28,000. The superinfectability of the defective
producers suggests that the cells lack ecotropic
glycoprotein and the virions are without spikes
when viewed with the electron microscope; vir-
ions lacking glycoprotein have been demon-
strated previously (5). We cannot be entirely
certain, however, that the particles lack glyco-
protein because a glycoprotein that does not
react with antiserum made against M-MuLV
gp70 could be present.
The defective virions could either originate
from the A-MuLV genome, represent alteration
of the helper virus, or derive from an endogenous
virus or some combination of these. The only
known product of the A-MuLV genome is a
120,000-molecular-weight protein (P120). Be-
cause an antiserum has been produced that fails
to precipitate A-MuLV P120 but reacts with
both M-MuLV p30 and the defective virion p28
(unpublished data), the A-MuLV genome is an
unlikely source for p28. Furthermore, because
the Abelson genome codes for only a small por-
tion of the major structural protein and lacks
coding capacity for the reverse transcriptase, it
is unlikely to code for any of the known com-
ponents of the defective virions. An alteration of
the helper virus is unlikely because defective
virions in lymphoid cells induced with another
strain of M-MuLV as helper (M-MuLV-TB),
contained p28 with an unaltered cleavage pat-
tern and one that was different from that of the
p30 of M-MuLV-TB. A modification of the
helper virus could have occurred, however, that
changed p30 to p28 and obliterated the helper's
characteristic peptide.
The defective virus could in principle derive
from a defective virus carried in our viral stocks.
Although the generation of defective producers
has been observed with several different well-
cloned stocks of virus, we cannot rigorously ex-
clude this explanation. We feel that the most
likely origin of the defective genome, however,
is from an endogenous mouse virus. When we
tested the only known endogenous virus of the
SWR/J mouse we found that its major struc-
tural protein had a size different from that of
p28. Although the cleavage patterns of the en-
dogenous virus p27 and defective virion p28 were
similar, there were minor differences. Analysis
of the DNA from many strains of laboratory
mice, however, has demonstrated the existence
of multiple genes with homology to M-MuLV
(31). The existence of another undetected en-
dogenous virus is quite possible because it ap-
pears to be without infectivity and might only
express itself in early lymphoid cells. In this
regard it is important to remember that endog-
enous viral genes are known to be expressed in
various tissues including B-lymphoid cells (1, 14,
30). We were unable to test uninfected lymphoid
cells of the same differentiation state as A-
MuLV-transformed cells because they could not
be propagated in culture.
Lymphoid cell transformation with A-MuLV
is significantly different from the transformation
of fibroblasts. This suggests that lymphoid cells
express virus in unique ways. The ability of
lymphoid cells to cease the production of helper
viruses and the release of defective virions by
J. VIROL.
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such cells may be reflections of their differen-
tiated state.
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